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Purpose: The most effective treatments in elderly patients with esophageal cancer remain a subject
of debate. This multicenter phase 2 study was designed to evaluate the efﬁcacy and toxicity of
chemoradiation therapy (CRT) with docetaxel (DTX) in elderly patients with stage II/III (non-T4)
esophageal cancer.
Methods and materials: Patients 70 years of age with clinical stage II/III esophageal cancer
received DTX at a weekly dose of 10 mg/m2 during 6 consecutive weeks and concurrent radiation
therapy (60 Gy in 30 fractions). The primary endpoint was the 2-year survival rate, and the required
number of enrolled patients was 37.
Results: Between July 2008 and January 2011, 16 patients were enrolled. The study was pre-
maturely closed because of slow accrual. Characteristics of the patients were as follows: median
age, 77 years (range, 73-81); performance status 0/1, 4/12; and clinical stage IIA/IIB/III, 3/4/9. Of
the 16 patients, 14 (87.5%) completed the CRT. The 2-year survival rate was 62.5%
(90% conﬁdence interval [CI], 42.5-82.5). The median survival time was 27.7 months (95% CI,Conﬂicts of interest: None.
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Advances in Radiation Oncology: OctobereDecember 2016 CRT with DTX in elderly EC 23123.3-32.2 months) and the median progression-free survival was 15.2 months (95% CI, 5.4-25.0
months). Seven patients achieved complete response, resulting in a complete response rate of
43.8% (95% CI, 19.8-70.1). Grade 3 or higher acute toxicities included esophagitis (31.3%),
anorexia (12.5%), leukopenia (6.3%), neutropenia (6.3%), thrombocytopenia (6.3%), mucositis
(6.3%), and infection (6.3%). Grade 3 or higher late toxicities included esophagitis (12.5%), pleural
effusion (12.5%), pneumonitis (6.3%), and pericardial effusion (6.3%).
Conclusions: CRT with DTX might be a treatment option for elderly patients with stage II/III
esophageal cancer, particularly for patients who are medically unﬁt for surgery or cisplatin-
containing therapy. However, further improvements of this therapy are required to decrease the
incidence of esophagitis.
Copyright ª 2016 the Authors. Published by Elsevier Inc. on behalf of the American Society for
Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Esophageal cancer is the sixth most common cause of
cancer-related mortality worldwide.1 In Japan, esopha-
geal cancer was responsible for 11,182 deaths in 2005,
accounting for 3.4% of the total cancer death in the
country. Of the 16,323 esophageal cancer cases in 2001
in Japan, 7585 (46.5%) were elderly patients older than
age 70 years.2 Surgery is still the mainstay treatment for
resectable esophageal cancer; however, because the in-
dications for radical surgery in elderly patients are not
well-deﬁned,3 these patients are less likely to undergo
surgery.4 Moreover, outcomes after esophagectomy in
elderly patients are controversial.5-7 Chemoradiation
therapy (CRT) is also a standard treatment for patients
with localized esophageal cancer. The Radiation Ther-
apy Oncology Group (RTOG) 85-01 trial demonstrated
the superiority of CRT with ﬂuorouracil (5-FU) and
cisplatin (CDDP) over radiation therapy alone in patients
with T1-3 N0-1 M0 esophageal cancer.8 In Japan, a
phase 2 trial for evaluating CRT with 5-FU and CDDP
for clinical stage II/III (non-T4) esophageal cancer
showed promising efﬁcacy with a complete response
(CR) rate of 62.2% and 3-year survival rate of 44.7% (9).
The 2-year survival rates were 36% in the CRT arm of
the RTOG 85-01 trial and 52.6% in the Japanese trial,
respectively. However, 23% of patients were older than
70 years in the RTOG 85-01 trial, and the eligibility for
the Japanese trial had an age range of 20 to 70 years. A
retrospective comparison of the outcomes of CRT with
5-FU and CDDP between elderly and nonelderly patients
with stage II/III (non-T4) esophageal cancer demon-
strated that elderly patients showed higher frequency of
hematologic adverse events, poor compliance, and
signiﬁcantly inferior survival. The 2-year survival rate
was 45% in elderly patients (71 years of age) compared
with 55% in nonelderly patients (<70 years of age) (10).
Another retrospective study concluded that elderly pa-
tients experienced substantial morbidity from CRT and
poor long-term survival.9 Thus, the most effectivetreatment modalities in elderly patients with esophageal
cancer remain a subject of debate, and new treatment
options with lower toxicity and higher efﬁcacy must be
developed.
Elderly patients sometimes show decreased renal
function or poor nutrition and are not considered suitable
for CDDP-containing therapy. Therefore, nonplatinum-
based CRT could be an optional regimen for elderly
patients. Anderson et al reported good results in 25
elderly patients (65 years of age) with esophageal
cancer treated with 5-FU, mitomycin-C, and radiation
therapy. The 2-year survival rate was 64% (95% conﬁ-
dence interval [CI], 45-83).10 Iyer et al evaluated erlotinib
combined with radiation therapy in 17 elderly patients
(>65 years of age) with esophageal cancer. Although this
treatment was tolerable, the 1-year survival rate was 29%
(95% CI, 11-51).11
Docetaxel (DTX) is an active agent for advanced
esophageal cancer.12,13 In addition to cytotoxic activity,
DTX has a radiosensitizing activity through its ability to
induce cell cycle blockade in G2-M.14,15 Promising ac-
tivity and manageable toxicity of CRT with DTX were
reported in non-small cell lung cancer and head and neck
cancer.16-19 In a previous phase 1 study in Japan, CRT
with weekly DTX was tolerable and effective in patients
with localized esophageal cancer, and the recommended
dose was determined to be DTX 10 mg/m2. CRT with
DTX was expected to be a new treatment option in elderly
patients who were medically unﬁt for surgery or CDDP-
containing therapy; therefore, we conducted a multi-
center phase 2 study of CRT with DTX in elderly patients
to evaluate efﬁcacy and toxicity.Methods and materials
Patients
For this phase 2 trial, patients were recruited from 9
hospitals in Japan. Patients 70 years of age with
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carcinoma, or adenosquamous cell carcinoma of the
thoracic esophagus who were not considered suitable for
CDDP-containing therapy were included. Clinical stage
II/III tumors, excluding T4 tumors according to the In-
ternational Union Against Cancer, 6th edition, were
eligible. Staging was performed by computed tomography
(CT) and endoscopic ultrasonography. Patients were
required to be Eastern Cooperative Oncology Group
(ECOG) performance status 0 or 1, meet the following
laboratory criteria within 14 days before registration:
white blood cells 3000/mm3; platelet count 10104/
mm3; hemoglobin level 8.0 g/dL; aspartate amino-
transferase and alanine aminotransferase 100 IU/L; total
bilirubin 1.5 mg/dL; serum creatinine 2.0 mg/dL; and
oxygen saturation 93%. Exclusion criteria were a his-
tory or current presence of other malignancies, previous
chemotherapy, or radiation therapy. Written informed
consent was obtained from all patients. The study was
undertaken in accordance with the protocol and approved
by the institutional review boards of the participating
institutions.
Chemotherapy
All patients received DTX at a dose of 10 mg/m2
weekly during 6 consecutive weeks. DTX was adminis-
tered through a 1-hour intravenous infusion on day 1 of
each cycle.
The Common Terminology Criteria for Adverse
Events (CTCAE), version 3.0, was used for evaluating
toxicity. Chemotherapy was delayed because of toxicities
until recovery to the following conditions: absolute
neutrophil count 1000/mm3; platelet count 7.5104/
mm3; aspartate aminotransferase and alanine amino-
transferase  100 IU/L; total bilirubin 2.5 mg/dL;
serum creatinine 2.5 mg/dL; and grade 2 or lower
nausea, vomiting, anorexia, esophagitis, diarrhea, or ra-
diation pneumonitis.
Radiation therapy
Radiation therapy was delivered using megavoltage
(6 MV) radiographs, with 2 Gy daily and 5 fractions per
week, on the ﬁrst day of chemotherapy. The total dose
was set at 60 Gy in 30 fractions. Three-dimensional
treatment planning was required. Target volumes were
determined according to the images acquired from the CT.
Primary tumor and metastatic lymph nodes were included
in the gross tumor volume. The clinical target volume
provided a 2-cm craniocaudal margin for the primary
tumor. Planning target volume was deﬁned as clinical
target volume plus a 1 to 2 cm margin in the craniocaudal
direction and a 0.5 to 1 cm margin in the lateral direction.
Elective nodal irradiation was not performed. Tissue
density inhomogeneity correction was used.Assessment
Tumor response was assessed by CT and esoph-
agogastroduodenoscopy (EGD), according to Response
Evaluation Criteria in Solid Tumors, version 1.0.20 CT
and EGD were carried out 4 weeks after treatment
completion and 4, 6, 9, and 12 months after the beginning
of the treatment in the ﬁrst year. In the second and third
years, follow-up examinations were conducted every 3
months and every 6 months thereafter. Primary tumor
response was evaluated by EGD using the modiﬁed
criteria of the 10th edition of Guidelines for Diagnosis
and Treatment of Carcinoma of the Esophagus, issued by
the Japanese Society for Esophageal Diseases.21 CR of
the primary tumor was deﬁned as the disappearance of the
primary tumor lesion, ulceration, erosion, and the absence
of malignant cells in biopsy specimens. CR of lymph
node metastases was deﬁned as the disappearance of all
visible lymph node metastases on CT imaging. Overall
CR was declared when CR at both the primary tumor and
the lymph node was obtained without the appearance of a
new lesion. Overall CR was conﬁrmed by reassessment 4
or more weeks after the ﬁrst assessment.
Acute toxicities were assessed weekly during CRT and
4 weeks after completion of CRT. Late toxicity was
deﬁned as an adverse event occurred more than 90 days
after CRT initiation. Toxicities were evaluated based on
the CTCAE, version 3.0.Statistical methods
The primary endpoint of this phase 2 trial was the 2-
year survival rate. Overall survival was deﬁned as the
time from the date of registration to that of death from any
cause, and it was censored at the date of the last follow-up
for survivors. The 2-year survival rate was estimated
using the Kaplan-Meier method. A retrospective study
showed the 2-year survival rate of 45% in elderly patients
(71 years of age) treated with CRT with 5-FU and
CDDP. We calculated the sample size expecting a 2-year
survival rate of 50%, with a 30% threshold. With a power
of 80% and 1-sided 5% signiﬁcance, the required number
of enrolled patients was 37. We ﬁnally planned to enroll
40 patients in total, including ineligible patients.
Secondary endpoints were progression-free survival
(PFS),CR rate, and acute and late toxicities. PFSwas deﬁned
as the time from the date of registration to that of disease
progression or death from any cause, and it was censored at
the date of the last visit for patients without progression.
Survival was estimated using Kaplan-Meier method.
The 2-year survival rate, overall survival, PFS, and CR
rate were calculated according to an intention-to-treat
population. Statistical analyses were performed using R
(version 3.1.2; R Foundation for Statistical Computing,
Vienna, Austria).
Table 1 Patient characteristics
Characteristics Number of patients
(n Z 16)
Percentage
(%)
Age (y)
Median 77
Range 73-81
Sex
Male 14 87.5
Female 2 12.5
ECOG PS
0 4 25.0
1 12 75.0
Histology
Squamous cell carcinoma 15 93.8
Adenocarcinoma 1 6.3
Tumor location
Upper thorax 2 12.5
Middle thorax 9 56.3
Lower thorax 5 31.3
T factor
T1 4 25.0
T2 1 6.3
T3 11 68.8
N factor
N0 3 18.8
N1 13 81.3
Stage (UICC 6th edition)
IIA 3 18.8
IIB 4 25.0
III 9 56.3
CCr (mL/min)
60 4 25.0
50-60 6 37.5
<50 6 37.5
CCr, creatinine clearance; ECOG PSZ Eastern Cooperative Oncology
Group performance status; UICC, International Union Against Cancer.
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Patient characteristics
Between July 2008 and January 2011, 16 patients were
enrolled. The study was prematurely closed because of
slow accrual. Baseline characteristics are summarized in
Table 1. The median age was 77 years (range, 73-81).
Four (25.0%) and 12 (75.0%) patients showed ECOG
performance status of 0 and 1, respectively. Most patients
(15 of 16 [93.8%]) had squamous cell carcinoma, whereas
the remaining patient had adenocarcinoma. The clinical
stages (International Union Against Cancer, 6th edition)
were IIA for 3 patients (18.8%), IIB for 4 patients
(25.0%), and III for 9 patients (56.3%).
Treatment
Of the 16 enrolled patients, 14 (87.5%) completed the
CRT according to the protocol. Two patients discontinued
protocol treatment because of grade 3 esophagitis (nZ 1)
and patient refusal not related to any adverse event (n Z
1). The patient who developed grade 3 esophagitis did not
receive the last cycle of chemotherapy and 4 Gy of ra-
diation therapy. The other patient received one cycle of
chemotherapy and 10 Gy of radiation therapy before
refusing to continue the treatment. After the evaluation of
CRT, 2 patients among the non-CR cases received addi-
tional chemotherapy with DTX.
Efﬁcacy
As of August 31, 2014, the median follow-up was 57.9
months. Twelve of 16 patients died at the time of analysis;
9 patients (75.0%) died as a result of progressive or
recurrent disease, 3 patients died from other cause. Seven
patients achieved CR, resulting in a CR rate of 43.8%
(95% conﬁdence interval [CI], 19.8-70.1). The median
PFS was 15.2 months (95% CI, 5.4-25.0 months), and the
median survival time was 27.7 months (95% CI, 23.3-
32.2 months), respectively. The 2-year survival rate was
62.5% (90% CI, 42.5-82.5) (Fig 1).
Toxicity
No treatment-related deaths were observed in any of
the 16 patients. Toxicities occurring during CRT are
shown in Table 2. Grade 3 or higher acute toxicities
included esophagitis (31.3%), anorexia (12.5%), leuko-
penia (6.3%), neutropenia (6.3%), thrombocytopenia
(6.3%), mucositis (6.3%), and infection (6.3%). Table 3
shows late toxicities associated with CRT. Grade 3 or
higher late toxicities included esophagitis (12.5%), pleural
effusion (12.5%), pneumonitis (6.3%), and pericardial
effusion (6.3%).Salvage or second-line treatment
The pattern of failure is shown in Table 4. Eight pa-
tients had residual or progressive disease: 5 patients had
residual or locoregional progressive disease only and 3
patients had distant metastasis. Two patients had locore-
gional recurrence after CR. Five patients who had residual
or locoregional progressive disease received the following
treatments: CRT with DTX in 3 patients, chemotherapy
with 5-FU and CDDP in 1 patient, and best supportive
care in 1 patient. Of the 3 patients with distant metastasis,
2 received palliative radiation therapy and 1 received
chemotherapy with 5-FU and nedaplatin. Of the 2 patients
with recurrent disease, 1 underwent salvage lymph node
dissection and 1 received best supportive care.
Discussion
The present study was designed to evaluate the efﬁ-
cacy and toxicity of CRT with DTX in elderly patients by
0 1 2 3 4 5 6
0.0
0.2
0.4
0.6
0.8
1.0
Time (years)
O
ve
ra
ll s
ur
viv
al
16 13 10 6 5 1 0
Number at risk
0 1 2 3 4 5 6
0.0
0.2
0.4
0.6
0.8
1.0
Time (years)
Pr
og
re
ss
io
n-
fre
e 
su
rv
iva
l
16 9 5 4 3 0 0
Number at risk
A B
Figure 1 (A) Overall survival and (B) progression-free survival.
Table 2 Adverse events during CRT (CTCAE, version 3.0)
Toxicity Number of patients (n Z 16) Grade
3 (%)Grade
1
Grade
2
Grade
3
Grade
4
Leukopenia 7 3 1 0 6.3
Neutropenia 1 1 0 1 6.3
Anemia 13 1 0 0 0
Thrombocytopenia 9 0 1 0 6.3
Creatinine 5 2 0 0 0
Anorexia 4 6 2 0 12.5
Nausea 6 1 0 0 0
Vomiting 4 2 0 0 0
Mucositis 0 0 1 0 6.3
Esophagitis 3 6 5 0 31.3
Diarrhea 2 0 0 0 0
Infection 0 0 1 0 6.3
Pneumonitis 4 1 0 0 0
CRT, chemoradiation therapy; CTCAE, Common Terminology
Criteria for Adverse Events.
234 A. Ohba et al Advances in Radiation Oncology: OctobereDecember 2016enrolling 37 eligible patients during 2 years. However, the
slow accrual led to premature closure, with only 16 pa-
tients enrolled. The main reason for this was that elderly
and frail patients were not usually willing to receive the
investigational treatment.
In our study, CRT with DTX in elderly patients with
stage II/III esophageal cancer produced a 2-year survival
rate of 62.5% (90% CI, 42.5-82.5), CR rate of 43.8%
(95% CI, 19.8-70.1), and median survival time of 27.7
months (95% CI, 23.3-32.2 months). A retrospective
study showed a 2-year survival rate of 45% in elderly
patients treated with CRT with 5-FU and CDDP; thus, in
this study, the expected 2-year survival rate was deﬁned
to be 50%, with a threshold of 30%. In spite of the
immature patient accrual, the lower limit of 90% CI for
the 2-year survival rate exceeded the threshold. Moreover,
the 2-year survival rate was higher compared with pre-
vious studies that did not target elderly patients. The 2-
year survival rates in the radiation therapy alone arm,
CRT arm of the RTOG 85-01 trial, and the Japanese
phase 2 trial of CRT with 5-FU and CDDP were 10%,
36%, and 52.6%, respectively.8,22 Though we should pay
attention to selection bias, CRT with DTX is expected to
have a similar efﬁcacy as CRT with 5-FU and CDDP, at
least greater than radiation therapy alone, in elderly pa-
tients. On the other hand, the CR rate was lower
compared with previous studies, probably because the
rate of acute and late esophagitis was higher in this study,
complicating the evaluation of a CR of the primary lesion.
For CR evaluation, we used the criteria of the Japan So-
ciety of Esophageal Disease, which state the disappear-
ance of esophagitis as a requirement to conﬁrm CR.21
Actually, of 9 non-CR or not examined patients, 3 were
not conﬁrmed CR because of esophagitis with CR of
lymph node metastases on CT imaging. Thus, the CR rate
of this study might have been underestimated.CRT with carboplatin and paclitaxel, another
platinum-based regimen, have been used widely since the
result of the Chemoradiotherapy for Oesophageal Cancer
Followed by Surgery Study (CROSS) trial was reported.23
Because of its favorable tolerance, this regimen also
seems to be suitable for elderly patients. However, the
eligibility of the CROSS trial was younger than 75 years
old, and the median age was 60 years. Moreover, carbo-
platin is not approved for esophageal cancer in Japan.
The major treatment-related toxicity was esophagitis.
Although hematologic or other nonhematologic toxic-
ities were not frequently observed, the rates of esoph-
agitis in both acute and late toxicities were higher
compared with previous studies. Furthermore, grade 3
or higher esophagitis was reported as acute (31.3%) or
Table 3 Late adverse events (CTCAE, version 3.0)
Toxicity Number of patients (n Z 16) Grade
3 (%)Grade 1 Grade 2 Grade 3 Grade 4
Esophagitis 4 4 2 0 12.5
Pleural
effusion
4 0 2 0 12.5
Pneumonitis 10 1 1 0 6.3
Pericardial
effusion
3 0 1 0 6.3
CTCAE, Common Terminology Criteria for Adverse Events.
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patients tend to develop esophagitis or the combination
of DTX and radiation therapy is highly toxic for the
esophageal mucosa. In a retrospective study, esophagitis
was relatively more common in elderly than in non-
elderly patients.24 For the latter, previous studies of
CRT with DTX in non-small cell lung cancer or head
and neck cancer reported high frequency of esophagitis
or mucositis.16-19 It is generally considered that a
reduction in the total radiation dose may decrease the
incidence of esophagitis. Because in Japan a radiation
dose of 60 Gy has been used in deﬁnitive CRT for
esophageal cancer, the present study was performed
with a total radiation dose of 60 Gy. However, the
Intergroup 0123 trial demonstrated that a higher irradi-
ation dose of 64.8 Gy offered no advantage in terms of
survival and local control compared with the standard
dose of 50.4 Gy.25 In addition to this, the Kitasato
Digestive Disease and Oncology Group 0501-P2 trial, a
phase 2 trial for evaluating CRT with DTX, CDDP, and
5-FU for advanced esophageal cancer with T4 or M1
lymphoma, showed that the incidence of grade 3 or
higher acute esophagitis decreased (41.6% to 23.3%)
and the CR rate improved (33.3% to 60.0%), by
reducing the total radiation dose from 61.2 Gy to 50.4
Gy.26 Therefore, a total radiation dose of 50.4 Gy can be
recommended for CRT with DTX.Table 4 Pattern of failure
Pattern Number of patients
(n Z 16)
Percentage
Alive without failure 3 18.8
Not examined 1 6.3
Any failure 12 75.0
Dead by other cause after
CR
2 12.5
Residual or PD 8 50.0
Locoregional 5 31.3
Distant 3 18.8
Recurrence after CR 2 12.5
Locoregional 2 12.5
Distant 0 0
CR, complete response; PD, progressive disease.A major limitation of this study is the small sample
size. In addition, there might be patient selection biases
because patients in relatively good conditions were
enrolled, thus leading to longer survival rates. Although
not planned, most patients had squamous cell carcinoma,
with only 1 patient having adenocarcinoma.
Even in elderly patients, standard treatments for
localized esophageal cancer are surgery and CRT with 5-
FU and CDDP; therefore, CRT with DTX seems to be an
optional treatment, particularly in patients who are
medically unﬁt for surgery or CDDP-containing therapy.
To validate the beneﬁt of this regimen, a prospective
randomized trial of CRT with DTX versus radiation
therapy alone will be required in the future.
Conclusions
In conclusion, CRT with DTX might be a treatment
option for elderly patients with stage II/III esophageal
cancer, particularly for patients who are medically unﬁt
for surgery or CDDP-containing therapy. However,
further improvements of the treatment are required to
decrease the incidence of esophagitis.References
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